Avelos Therapeutics
June 05, 2024
Company Presentation

Company Presentation Theater 1
- Avelos is a cutting-edge science based oncology drug development company, particularly focusing on small molecule drugs for novel targets in the areas of synthetic lethality, DNA damage repair and cell cycle. - The company was founded in Sep. 2021, and is headquartered in Seoul. - The founding members include Young-Whan Park (ex-Merck), Soongyu Choi (ex-Bayer), Kangsik Yun (ex-National Oncoventure), who have strong expertise and networks in new drug discovery and development. - Currently, Avelos has 4 oncology drug programs. AVS1001, the first-in-class DNA damage repair & cell cycle inhibitor program, is in IND enabling stage, the others are in lead optimization stage. - The company closed a $8 million Series A financing in 2022, and Series B financing is ongoing.
.png)
Company Website:
http://www.avelostx.com
Lead Product in Development:
- AVS1001 : Oncology, NCE, Cell cycle and DNA Damage Response target (preclinical)
- AVS1002 : Oncology, NCE, DNA Damage Response target (Discovery)
- AVS1003 : Oncology, NCE, DNA Damage Response target (Discovery)
- AVS1004 : Oncology, NCE, DNA Damage Response target (Discovery)
Number Of Unlicensed Products (For Which You Are Seeking Partners):
4 oncology drug products
Company HQ City
Seoul
Company HQ State
Seoul
Company HQ Country
Korea, Republic of
CEO/Top Company Official
- CEO : Dr. Young-Whan Park
- CTO : Dr. Soongyu Choi
- Head of BD : Mr. Kangsik Yun
Development Phase of Primary Product
Pre-Clinical
Speakers